成人无码高潮av在线观看_欧洲极品少妇_夂久亚州精华国产精华华液_在线观看亚洲AV每日更新无码_亚洲国产精品无码久久一线_亚洲精品区午夜亚洲精品区

法國Nicox
法國生物技術公司Nicox

NicOx is a pharmaceutical company focused on the research, development and future commercialization of drug candidates. NicOx is applying its proprietary nitric oxide-donating R&D platform to develop an internal portfolio of New Molecular Entities (NMEs) for the potential treatment of inflammatory, cardiometabolic and ophthalmological diseases.

Resources are focused on the development and pre-commercialization activities for naproxcinod, a proprietary NME and the first-in-class Cyclooxygenase-Inhibiting Nitric Oxide-Donating (CINOD) anti-inflammatory agent developed for the relief of signs and symptoms of osteoarthritis. Naproxcinod is currently under review by regulatory authorities, following the submission and filing of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) and a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA). The FDA plans to hold a meeting of the Arthritis Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee to discuss naproxcinod’s New Drug Application (NDA) on May 12, 2010 and has set a target PDUFA date of July 24, 2010 for the completion of its review.

In addition to naproxcinod, NicOx’s pipeline includes several nitric oxide-donating NMEs, which are in development internally and with partners, including Merck & Co., Inc. and Bausch + Lomb, for the treatment of hypertension, cardiometabolic diseases, widespread eye diseases and dermatological disease.

NicOx aims to build itself into a fully integrated specialty pharmaceutical company, with its own sales force targeting specialist physicians in the United States, as well as innovative internal R&D programs.

NicOx has strategic partnerships, collaborative agreements and research alliances with some of the world's leading pharmaceutical companies and specialist players, which allow it to maximize the value of its technology and broad portfolio, while allowing the Company to retain future commercialization rights in select areas.